New Perspectives and New Targets in Optimizing Treatment of DED (CE Monograph)

Activity Description and Purpose

This educational activity is based on the proceedings of an expert roundtable that took place on March 15, 2024, in New York, New York. This activity presents an overview of dry eye disease (DED), its pathophysiology, and clinical trial evidence supporting the role of new therapies. Through expert case-based discussions, participants will learn approaches for efficient DED diagnosis and management strategies. The desired results of this activity are to cement clinicians’ knowledge of and competence in developing practical strategies for the diagnosis and treatment of DED.

Target Audience

This educational activity is intended for optometrists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Incorporate diagnostic strategies for DED into practice
  • Review the pathophysiologic factors of DED
  • Design evidence-based treatment plans for patients with DED
Course summary
Available credit: 
  • 1.50 COPE
Course opens: 
07/31/2024
Course expires: 
07/31/2025

Faculty

Marc Bloomenstein, OD, FAAO (Chair)
Director of Optometric Services
Schwartz Laser Eye Center
Scottsdale, Arizona
Lindsey A. Bull, OD, FAAO
EyeCare Associates of South Tulsa
Tulsa, Oklahoma
Douglas K. Devries, OD
Associate Clinical Professor
Pacific University College of Optometry
Co-Founder
Advanced Vision and Laser Center
Reno, Nevada
Jessilin Quint, OD, MBA, MS
Smart Eye Care
Augusta, Maine

Disclosure Policy

MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity. All relevant relationships have been mitigated.

Faculty

Marc Bloomenstein, OD, is an advisory board member of AbbVie Inc, Alcon, Astellas Pharma Inc, Bausch & Lomb Incorporated, Bruder Healthcare, Harrow, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, OcuSOFT Inc, Oyster Point Pharma, Inc, Reichert, Inc, Sight Sciences, STAAR Surgical, Sun Pharmaceutical Industries, Inc, Sydnexis Inc, Tarsus Pharmaceuticals, Inc, Thea Pharmaceuticals Limited, and Topcon Medical Systems, Inc; and is on the speakers bureau for AbbVie Inc, Bausch & Lomb Incorporated, Dompé US, Inc, Oyster Point Pharma, Inc, Sight Sciences, Sun Pharmaceutical Industries, Inc, and Tarsus Pharmaceuticals, Inc.

Lindsey A. Bull, OD, is a consultant for AbbVie Inc, Kala Pharmaceuticals*, and Viatris Inc.

Douglas K. Devries, OD, is a consultant for AbbVie Inc, Alcon, Avellino, Azura Ophthalmics Ltd, Bausch & Lomb Incorporated, Bruder Healthcare, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Lumenis, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Oyster Point Pharma, Inc, ScienceBased Health, Sight Sciences, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, Thea Pharmaceuticals Limited, and Visus Therapeutics; and is on the speakers bureau for Alcon, Bausch & Lomb Incorporated, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Lumenis, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Oyster Point Pharma, Inc, ScienceBased Health, Sight Sciences, and Sun Pharmaceutical Industries, Inc.

Jessilin Quint, OD, MBA, MS, is a consultant for AbbVie Inc, Alcon, Bausch & Lomb Incorporated, Dompé US, Inc, Eyenovia, Inc, Lumenis, Ocuphire Pharma, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Tarsus Pharmaceuticals, Inc, and Viatris Inc; and is on the speakers bureau for AbbVie Inc, Alcon, and Bausch & Lomb Incorporated.

* The financial relationship existed during the past 24 months but has now ended

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners, Managers, and Writers

MedEdicus planners and managers have no relevant commercial relationships to disclose.

Medical Writer: Cheryl Guttman Krader has individual stocks in AbbVie Inc and Johnson & Johnson Vision Care, Inc.

Accreditation Statement

 COPE approved for 1.5 CE credits for optometrists.
COPE Course ID: 92454-TD (Asynchronous)
COPE Course Category: Treatment/Management of Ocular Disease

Administrator:

This activity, COPE Activity Number 128886, is accredited by COPE for continuing education for optometrists.

Disclosure of Commercial Support

MedEdicus has received commercial support from Bausch & Lomb Incorporated for this activity in the form of an unrestricted educational grant.

The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs or devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Sponsored by

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the State University of New York College of Optometry, MedEdicus LLC, or Bausch & Lomb Incorporated.

This CE activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 319.2

Available Credit

  • 1.50 COPE
Please login or register to take this course.

Clicking Register/Take course indicates that you have reviewed the CE information for this activity.